• Теги
    • избранные теги
    • Компании117
      • Показать ещё
      Формат7
      Страны / Регионы18
      • Показать ещё
      Разное15
      • Показать ещё
      Международные организации1
      Показатели5
      Сферы1
      Издания1
      Люди3
Eli Lilly & Co
09 января, 17:11

Why PRIMECAP Odyssey Growth Fund (POGRX) Worth Another Look?

PRIMECAP Odyssey Growth Fund (POGRX) seeks capital appreciation

15 ноября 2016, 22:31

Investing in a Cure for Cancer: What You Need to Know

By 2030, the number of new cancer cases per year is expected to rise by 70%. How does cancer work, and why isn't there a cure yet? The post Investing in a Cure for Cancer: What You Need to Know appeared first on Visual Capitalist.

Выбор редакции
01 ноября 2016, 01:42

Biogen to invest $92 million in Puerto Rico, create 350 jobs

U.S. drugmaker Biogen Inc. is investing more than $92 million in Puerto Rico after buying assets that once belonged to Eli Lilly & Co. in the island’s southern region.

05 октября 2016, 00:26

Pence, Kaine Share Long Histories In The Fundraising Trenches

Mike Pence of Indiana has raised funds for six House races and two gubernatorial campaigns, the second of which was aborted when he was added to the GOP's presidential ticket.  (AP Photo/Charlie Neibergall, File) By: Jack Noland Though divided ideologically, Indiana's Republican Gov. Mike Pence and Democratic Sen. Tim Kaine of Virginia have traced similar paths through state and federal politics on their way to being nominated for vice president. Both have served in Congress and as governors, and now hope to assume the government's second-from-the-top job. Though they may not discuss it tonight during the campaign's only vice presidential debate, their common ground extends to fundraising, too -- at least in broad strokes. The two have relied on lawyers, Wall Street types and a handful of other well-heeled individuals to raise the copious sums they've needed for their past campaigns. A Hoosier's hunt for cash Mike Pence, tonight's surrogate for GOP White House nominee Donald Trump, was elected to the House six times, collecting $1.1 million for his first run in 2000 and almost $2.7 million for his final contest; his 12-year haul came to more than $10.3 million. After retirees, who contributed $716,789 to Pence's congressional campaigns and leadership PAC (it's not unusual for seniors to be No. 1 on any candidate's list of top donors), the securities and investment industry -- aka Wall Street -- was his most generous industry, kicking in $376,311. Lawyers and law firms were third, providing $337,914. The governor's top donors fall outside those industries, however. The conservative Club for Growth donated $90,762 to Pence's congressional campaigns through its PAC and earmarked contributions from individuals. Cummins Inc, an engine manufacturer, and Eli Lilly & Co, a pharmaceutical company, round out Pence's top three campaign contributors. Employees and PACs of these Indiana-based corporations gave $78,500 and $64,350, respectively. When Pence ran for governor of Indiana in 2012, he raised more than $14.8 million -- including $425,000 from the late Dean White, a billionaire businessman from the state; that made White Pence's top individual donor that year. Big shots of party cash came via the Republican Governors Association and the Indiana Republican Party, which gave $1.1 million and $811,504, respectively. Pence also picked up $220,000 and $200,000 contributions from conservative bigwigs like Texas homebuilder Bob Perry, who passed away in 2013, and billionaire industrialist David Koch. After joining the presidential ticket in July, Pence dropped his 2016 re-election bid, having already raised more than $16.1 million. The RGA, Pence's top funder in 2012, had contributed more than $3 million, and the governor also collected $300,634 from Anthony Moravec, the CEO of Columbus-based Applied Laboratories, Inc., and another $100,000 from David Koch. White, who died in September, also contributed $350,000 to Pence's 2016 reelection effort. Trump and the governor will be unable to cultivate much hedge fund or private equity industry cash in 2016 -- at least not directly. That's because the SEC's so-called pay-to-play rule, implemented in 2010, caps the amount "SEC registered hedge fund advisers" can contribute to sitting state or local officials at $250-$350. Designed to prevent bankers and politicians from exchanging campaign contributions for the lucrative right to manage state pension funds, the rule triggered a Goldman Sachs memo banning certain categories of employees from donating to campaigns that feature a sitting state or local official. The Trump-Pence ticket is specifically listed as an example of a campaign to which employees may not contribute. Are there workarounds? Sure, including gifts to the Republican party. Pence's personal finances are less robust than his campaign coffers. His net worth in 2012 was estimated at $211,511. New documents are no more revealing: Pence's 2016 financial disclosure form reports his $173,860 gubernatorial salary and lists student loans for his children's education as his only liabilities. Multiple Kaine candidacies required millions Tim Kaine has moved relatively quickly between jobs over his political career. He was mayor of Richmond, lieutenant governor and then governor of Virginia, chairman of the Democratic National Committee and finally U.S. senator, the position he still holds, in a span of 18 years. Democrat Tim Kaine of Virginia has had to raise money to run for mayor of Richmond, lieutenant governor and governor, and senator -- and a huge part of his job at the DNC involved harvesting cash for his party. (AP Photo/Chuck Burton, File) For his 2001 lieutenant governor's race, Kaine raised almost $2.4 million, according to National Institute on Money in State Politics records. At the top, his haul included $50,000 from the DNC and $40,000 from Virginia real estate magnate Gerald Halpin. When Kaine ran for governor in 2005, he ratcheted up his fundraising efforts, collecting more than $18 million over the course of the cycle. Like Pence, he benefited from hefty cash infusions from the party, including $1.5 million from the DNC and $685,242 from the Virginia Democratic Party. Kaine also earned $662,964 in unitemized (small) donations and did well with unions, too: the SEIU, Laborers Local 980, Virginia AFL-CIO and IBEW each kicked in six-figure contributions. Among individuals backing Kaine, billionaire Sheila Johnson, who cofounded Black Entertainment Television and now heads Salamander Hotels and Resorts, made six donations worth a total $392,490 that year. Cisco Systems cofounder Sandy Lerner and real estate developer B. Mark Fried each gave Kaine more than $175,000. After leaving Richmond and serving as the chairman of the DNC (where corralling cash was a major part of the job), Kaine ran in 2012 for the Senate seat fellow Democrat Jim Webb announced he would be vacating. Kaine ultimately outraised Republican former Sen. George Allen in the general election, pulling in $18 million to his opponent's $14.5 million. Over the course of his Senate career, Kaine has raised the most cash from lawyers and affiliated PACs, taking in more than $2.7 million. Like Pence, he has benefited from heavy support from retirees, who have given the senator more than $2.1 million. Employees and PACs in the securities and investment industry come in at No. 3 on Kaine's list, having contributed almost $1.1 million. Kaine's top contributor has been JStreetPAC, a liberal pro-Israel group, leads the way. The PAC and individuals earmarking gifts to Kaine through it have provided him with $178,283 during his Senate run and since. Running just behind is the League of Conservation Voters, which also passed along gifts marked for Kaine; it provided $177,129. Employees of Covington & Burling, a D.C.-based law firm, gave more than $100,000. Kaine's net worth, estimated to be roughly $1.45 million in 2014, was far below the Senate average of $10.2 million. The senator's single outstanding liability then was a 15-year mortgage, and his financial reports list his board memberships at the Myotonic Dystrophy Foundation and the US-Spain Council. Kaine's income tax returns, released in August, show that he and his wife, former Virginia Secretary of Education Anne Holton, together earned $313,441 last year. While Kaine was lieutenant governor and then governor, he also accepted more than $160,000 worth of gifts, including vacation lodging, clothes and airfare, Politico reported. While the gifts were properly disclosed and legally permissible under Virginia law, the state's in-kind donation laws recently came into the spotlight when the U.S. Supreme Court in June unanimously overturned former Virginia Gov. Bob McDonnell's (R) ethics conviction, which stemmed from undisclosed gifts and charges of quid-pro-quo corruption. Pence and Kaine face off at Longwood University in Farmville, Va., tonight at 9 p.m. ET. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.

Выбор редакции
26 июля 2016, 15:35

Квартальные продажи Eli Lilly превысили прогнозы аналитиков

Американская фармацевтическая компания Eli Lilly & Co представила финансовые результаты за три месяца с окончанием в июне. Так, прибыль составила $747,7 млн или 71 цент на акцию по сравнению с $600,8 млн или 56 центами на бумагу годом ранее. Заметим, что прибыль за исключением некоторых статей сократилась с 90 центов на акцию годом ранее до 86 центов на бумагу, что совпало с ожиданиями рынка. Продажи, тем временем, увеличились на 8,6% г/г и составили $5,4 млрд, тогда как аналитики прогнозировали $5,15 млрд.

Выбор редакции
26 июля 2016, 14:51

Квартальные продажи Eli Lilly превысили прогнозы аналитиков

Американская фармацевтическая компания Eli Lilly & Co представила финансовые результаты за три месяца с окончанием в июне. Так, прибыль составила $747,7 млн или 71 цент на акцию по сравнению с $600,8 млн или 56 центами на бумагу годом ранее. Заметим, что прибыль за исключением некоторых статей сократилась с 90 центов на акцию годом ранее до 86 центов на бумагу, что совпало с ожиданиями рынка. Продажи, тем временем, увеличились на 8,6% г/г и составили $5,4 млрд, тогда как аналитики прогнозировали $5,15 млрд.

26 июля 2016, 14:00

Сегодня в США ожидается шквал информации

Во вторник, 26 июля, в Соединенных Штатах Америки ожидается публикация ряда важных макроэкономических показателей. В 17:00 МСК будет представлена информация по продажам нового жилья за июнь. Согласно прогнозам, показатель составил 0,560 млн после 0,551 месяцем ранее. В это же время будет опубликован индекс потребительского доверия за июль. Отметим, что в прошлом месяце он составил 98 пунктов. Среди второстепенных данных можно отметить недельные индексы сопоставимых продаж в розничных сетях, включая данные Красной книги. О квартальных результатах сегодня отчитаются компанииVerizon Communications, Caterpillar,EI du Pont de Nemours & Co, Freeport-McMoRan, Eli Lilly & Co, McDonald's, 3M, United Technologies, KeyCorp, Valero Energy, Centene (до открытия), а также Apple, Linear Technology, Juniper Networks (после закрытия).

25 июля 2016, 15:24

Сегодня в США ожидается шквал информации

Во вторник, 26 июля, в Соединенных Штатах Америки ожидается публикация ряда важных макроэкономических показателей. В 17:00 МСК будет представлена информация по продажам нового жилья за июнь. Согласно прогнозам, показатель составил 0,560 млн после 0,551 месяцем ранее. В это же время будет опубликован индекс потребительского доверия за июль. Отметим, что в прошлом месяце он составил 98 пунктов. Среди второстепенных данных можно отметить недельные индексы сопоставимых продаж в розничных сетях, включая данные Красной книги. О квартальных результатах сегодня отчитаются компании EI du Pont de Nemours & Co, Freeport-McMoRan, Eli Lilly & Co, McDonald's, 3M, United Technologies, KeyCorp, Valero Energy, Centene (до открытия), а также Apple, Linear Technology, Juniper Networks (после закрытия). К 13:45 МСК фьючерсы на индекс S&P 500 торгуются с понижениемна 0,080%.

Выбор редакции
26 апреля 2016, 16:23

Квартальная выручка Eli Lilly превысила прогнозы аналитиков

Американская фармацевтическая компания Eli Lilly & Co представила финансовые результаты за первый квартал. Согласно отчету компании, чистая прибыль составила $440 млн или 41 цент на акцию по сравнению с прибылью в $530 млн или 50 центов на бумагу годом ранее. Между тем, прибыль за исключением некоторых статей оказалась на уровне 83 центов на акцию, тогда как аналитики прогнозировали 85 центов. Выручка в рассматриваемом периоде возросла на 5% г/г до $4,87 млрд, хотя аналитики ожидали $4,82 млрд.

Выбор редакции
26 апреля 2016, 14:50

Квартальная выручка Eli Lilly превысила прогнозы аналитиков

Американская фармацевтическая компания Eli Lilly & Co представила финансовые результаты за первый квартал. Согласно отчету компании, чистая прибыль составила $440 млн или 41 цент на акцию по сравнению с прибылью в $530 млн или 50 центов на бумагу годом ранее. Между тем, прибыль за исключением некоторых статей оказалась на уровне 83 центов на акцию, тогда как аналитики прогнозировали 85 центов. Выручка в рассматриваемом периоде возросла на 5% г/г до $4,87 млрд, хотя аналитики ожидали $4,82 млрд.

Выбор редакции
05 января 2016, 18:33

Eli Lilly пересмотрела прогнозы на 2016 год

Американская фармацевтическая компания Eli Lilly & Co. пересмотрела прогнозы по прибыли и выручке на 2016 год. Так, по обновленным оценкам компании, выручка составит $20,2-20,7 млрд, а скорректированная прибыль на одну акцию может достичь $3,45-3,55. Заметим, что аналитики в среднем прогнозируют прибыль на акцию на уровне $3,65 при выручке в $21,6 млрд.

23 октября 2014, 14:15

Сегодня в США ожидается: данные по рынку труда, отчетности General Motors, Microsoft, Caterpillar и

В четверг, 23 октября, в Соединенных Штатах Америки ожидается публикация лишь одного важного макроэкономического показателя, а именно количества первичных обращений за пособиями по безработице за минувшую неделю (в 16:30 МСК). Согласно нашим прогнозам, количество обращений составило 282 тыс. после 264 тыс. неделей ранее. Из второстепенной статистики на сегодня можно отметить индекс деловой активности в промышленности, индекс экономической активности ФРБ Чикаго, индекс деловой активности в промышленности ФРБ Канзаса и недельное изменение запасов природного газа. В календаре корпоративных отчетностей значатся следующие компании: - 3М, American Airlines, Caterpillar, Celgene, Coca-Cola Enterprises, General Motors, KKR & Co., Eli Lilly & Co., Lorillard, Pulte Group, Union Pacific (до открытия торгов); - Amazon.com, Microsoft (после закрытия сессии). К 14:14 МСК фьючерсы на индекс S&P 500 торгуются с повышением на 0,509%.

23 октября 2014, 13:21

Сегодня в США ожидается: данные по рынку труда, отчетности General Motors, Microsoft, Caterpillar и

В четверг, 23 октября, в Соединенных Штатах Америки ожидается публикация лишь одного важного макроэкономического показателя, а именно количества первичных обращений за пособиями по безработице за минувшую неделю (в 16:30 МСК). Согласно нашим прогнозам, количество обращений составило 282 тыс. после 264 тыс. неделей ранее. Из второстепенной статистики на сегодня можно отметить индекс деловой активности в промышленности, индекс экономической активности ФРБ Чикаго, индекс деловой активности в промышленности ФРБ Канзаса и недельное изменение запасов природного газа. В календаре корпоративных отчетностей значатся следующие компании: - 3М, American Airlines, Caterpillar, Celgene, Coca-Cola Enterprises, General Motors, KKR & Co., Eli Lilly & Co., Lorillard, Pulte Group, Union Pacific (до открытия торгов); - Amazon.com, Microsoft (после закрытия сессии). К 14:10 МСК фьючерсы на индекс S&P 500 торгуются с понижением на 0,2%.

Выбор редакции
16 июня 2014, 22:27

Eli Lilly & Co. declares $0.49 dividend

Eli Lilly and Company (LLY) declares $0.49/share quarterly dividend, in line with previous.Forward yield 3.33%.Payable Sept. 10; for shareholders of record Aug. 15; ex-div Aug. 13. Post your comment!

16 мая 2014, 22:03

Bribery, Fraud and Corruption Charges Against Big Pharma

Catherine Frompovich Activist Post What happens when the ‘Average Joe’ gets caught committing a crime? He or she usually gets the book thrown at them, most often spending time in the slammer. However, what happens when “corporations too big to fail” get caught with “their hands in the cookie jar,” so to speak? Not very many folks pay the time, but the corporate treasury pays the fine. Why? Apparently, large sums of money can “absolve corporate sins” time after time after time. One industry that has had enormous fines levied against it is the pharmaceutical industry, also known as Big Pharma. It is the opinion of this writer that Big Pharma’s corporate largess is too tempting to resist by federal government agencies, and fines work nicely. Pharma’s lobbyists spend hundreds of millions of dollars a year contributing to congressional campaign coffers, which should be outlawed because it is nothing short of bribery—plain and simple. Obviously, a member of Congress will champion a cause – or is ‘morally’ obligated to do so – for the money Pharma’s lobbyists freely hand out. [3] That being said, let’s change gears and consider only a fraction of apparent crimes and misdemeanors Big Pharma and/or its personnel allegedly have perpetrated. Some have resulted in fines while others – if not many – slid under the wire or evaded the radar screen. One in that particular category, which comes to mind, is the inclusion of the SV-40 cancer-causing virus in the polio vaccine until about the early 1970s. Here and here are two articles about viruses in vaccines, which should have been prosecuted under the category “crimes against humanity.” How come? Well, when federal and state health agencies mandate that children be given vaccines that undoubtedly are not safe nor proven to not contain viruses or mycoplasma that cause diseases down the line, then both Big Pharma and government agency personnel ought to be prosecuted, in my opinion. Maybe we’d have ‘safer’ vaccines? Another equally questionable and seemingly non-prosecutable crime to date is the apparent research fraud perpetrated by Dr. Poul Thorsen, whom the U.S. CDC apparently ‘cannot find’ to prosecute regarding “fraud and embezzlement and the Danish vaccine-autism studies.” Here are a few articles that lay out that serious fraud, which the CDC apparently still stands behind and accepts Thorsen’s findings—ouch! Central Figure in CDC Vaccine Cover-Up Absconds with $2M The curious case of Poul Thorsen, fraud and embezzlement, and the Danish vaccine-autism studies  The Dangerous “EXPERTS” You Should Never Believe…   (adsbygoogle = window.adsbygoogle || []).push({});  Back in September of 2012, Forbes published the article “Big Pharma’s Offshore Fraud Strategy” [1] wherein this appears in the very first paragraph: …not to mention billion dollar liabilities for fraudulent marketing practices in the U.S. So, how can U.S. patients, i.e., healthcare consumers, trust or believe in all the pharmaceuticals their physicians so freely prescribe, apparently at the behest of Pharma representatives? Ever go to a doctor’s office and see a Pharma rep with his/her suitcases filled with samples waiting patiently to be squeezed into doctor’s busy patient schedule? Erica Kelton, who wrote that Forbes article, said pharmaceutical companies continue to pay “record criminal and civil fines in the U.S. for illegal marketing practices.” There’s a key word in that remark: fines! As long as Big Pharma can make billions of dollars in sales annually, it can continue its illegal marketing practices because the feds will get their ‘fair share’ of the profits from pharmaceutical sales, I contend. Both should be considered criminal activity on the part of federal government agencies and Big Pharma because Pharma continues to do the same thing again and again, only to be fined again and again. Can readers perceive the apparent profit cycle, especially at your expense both health-wise and monetarily? Regarding bribery, Kelton states: Pfizer, the world’s largest drugmaker, paid $60.2 million last month [August 2012] to the U.S. to settle charges that the company bribed government officials – including hospital administrators, government doctors and members of regulatory and purchasing committees — in China, Russia, Italy, Bulgaria, Croatia, Serbia and Kazakhstan to approve and prescribe Pfizer products. See how a round-robin cycle apparently works! And, ostensibly, it’s an ongoing thing. Reuters reported on May 14, 2014 that “4-Chinese police charge British former head of GSK in China with bribery.”  Also that Other large international drugs manufacturers including Novartis AG, AstraZeneca Plc, Sanofi SA , Eli Lilly & Co and Bayer AG were also visited by Chinese officials in 2013 as part of a broad investigation into the business. What is it that everyone doesn’t seem to be getting about Big Pharma that they get about other criminals such as sex offenders, i.e., when you do the crime, you pay the time. Sex offenders prey on relatively few victims as compared to the millions that Big Pharma’s fraud and deceit impact. Obviously, Big Pharma has not been playing by the rules—otherwise, why the fines, yet we entrust them to make the medicines that supposedly make us well—or is that a sham too? How can we trust them, if they are dishonest with regard to some business practices? Furthermore, Erica Kelton points out that in 2009 Pfizer paid $2.3 billion “for improper and illegal marketing of certain prescription drugs in the U.S.” Seemingly, Big Pharma is not prosecutable for crimes—only fines—which appear to be a ‘cash cow’ for the U.S. Treasury. How about all the taxes the U.S. collects on each vaccine sold along with apparently holding patents on some vaccines? Caching, caching goes the cash register. Can that be a reason for mandating more and more vaccines be injected into more and more people from birth to very old age? Should we follow the money? as they say. Are pharmaceutical crimes not prosecuted and people-perpetrators not sent to prison so that Big Pharma can create more revenue for the U.S. treasury? Is that why the pharmaceutical industry apparently can do whatever it wants, and as often as it wants, as long as it can pony up fine money? It seems that is a never-ending, fine-generating-cycle that has become engrained in the pharmaceutical culture—business as usual. Most often healthcare consumers wind up being at risk; note class action lawsuits. Still, Congress nor the U.S. CDC or FDA do nothing to close down operations or prosecute Pharma executives with prison time. When will that stop? Probably when healthcare consumers finally realize how they’ve been taken for a sleigh ride about pharmaceuticals and vaccines, I contend. To further elucidate and attest to my statements above about ‘criminal cycles’ and ‘cash cows’, Kelton notes several fines Big Pharma paid. GlaxoSmithKline paid $3 billion in July [2012] — which was the largest healthcare settlement ever — as well as $237 million in 2008 to settle two separate cases. Bristol-Myers paid $389 million in 2008. AstraZeneca paid $520 million in 2010 and $266 million in 2003. [1] In another Forbes article “Is Big Pharma Addicted to Fraud?” Kelton states that GlaxoSmithKline paid $750 million in 2009 to resolve civil and criminal charges. [2] Furthermore, Eli Lilly & Co. paid $29.4 million to settle allegations that they had bribed government officials and others in China. One law firm – Katz, Marshall and Banks, LLP – advertises as a law firm representing “Pharmaceutical Industry Whistleblowers.” Here’s the question this writer has to ask about whistleblowers: Where are they at the CDC and FDA? Probably the most comprehensive overview of the criminality factor within Big Pharma is found in the Health Ranger, Mike Adams’s 2012 article “Big Pharma Criminality in Vaccines,” but still nothing changes! This writer has come to a sad conclusion that nothing probably ever will change because pharmaceutical criminality truly IS cost effective behavior as far as the U.S. federal government is concerned—just pay the fines. Now that everyone ought to realize what’s apparently going on, the obvious solution to the problem seemingly lies with consumers who must re-educate themselves away from believing all the advertising bunk that’s been bullied into them by TV ads, public service announcements, and even the family doctor, who should know better. Family physicians should be the very ones to stand up, blow the whistle and say this is not correct, as Dr. Oz did in his recent TV show regarding heavy metals found in organic foods that he has recommended to his patients. Applause, applause, applause! Dr. Oz’s oft-repeated question during that show was to ask why FDA didn’t find what Mike Adams and his Forensic Food Lab found. This writer ventures to say that FDA really doesn’t give a hoot, especially when it can go after ‘big fish’ money from Big Pharma – something like an annuity – as long as the U.S. consumer buys into the ‘legal illegal’ activities that are carried out in the name of pharmaceutical science, which Big Pharma apparently gets away with. Notes:   [1] http://www.forbes.com/sites/erikakelton/2012/09/11/big-pharmas-offshore-fraud-strategy/ [2] http://www.forbes.com/sites/erikakelton/2013/07/29/is-big-pharma-addicted-to-fraud/ [3] http://www.huffingtonpost.com/2012/02/01/auction-2012-drug-companies-lobby_n_1245543.html Resources:   The New York Times / Glaxo Agrees to Pay $3 Billion in Fraud Settlement http://www.nytimes.com/2012/07/03/business/glaxosmithkline-agrees-to-pay-3-billion-in-fraud-settlement.html?pagewanted=all&_r=0 Natural News launches Labs reference website with heavy metals results for foods, organics, supplements and more http://www.naturalnews.com/043422_heavy_metals_lab_tests_organic_foods.html Unacceptable Levels / A film about 80,000 chemicals in products on the market http://www.yekra.com/unacceptable-levels/#!/deployment_code=24408257n5aopv Patent Landscape Report on Vaccines for Selected Infectious Diseases, November 2011 http://www.wipo.int/export/sites/www/freepublications/en/patents/946/wipo_pub_946_3.pdf Catherine J Frompovich (website) is a retired natural nutritionist who earned advanced degrees in Nutrition and Holistic Health Sciences, Certification in Orthomolecular Theory and Practice plus Paralegal Studies. Her work has been published in national and airline magazines since the early 1980s. Catherine authored numerous books on health issues along with co-authoring papers and monographs with physicians, nurses, and holistic healthcare professionals. She has been a consumer healthcare researcher 35 years and counting. Catherine’s latest book, published October 4, 2013, is Vaccination Voodoo, What YOU Don’t Know About Vaccines, available on Amazon.com. Her 2012 book A Cancer Answer, Holistic BREAST Cancer Management, A Guide to Effective & Non-Toxic Treatments, is available on Amazon.com and as a Kindle eBook. Two of Catherine’s more recent books on Amazon.com are Our Chemical Lives And The Hijacking Of Our DNA, A Probe Into What’s Probably Making Us Sick (2009) and Lord, How Can I Make It Through Grieving My Loss, An Inspirational Guide Through the Grieving Process (2008). 

22 апреля 2014, 14:51

Швейцария/Великобритания: Novartis приобретет одно из подразделений GSK за $16 млрд

Швейцарская фармацевтическая компания Novartis заключила соглашение по приобретению подразделения GlaxoSmithKline (GSK), занимающегося разработкой лекарства от рака, за $16 млрд. В свою очередь, Novartis намерена продать свое подразделение по охране здоровья животных американской фармацевтической компании Eli Lilly & Co за $4,5 млрд, а также подразделение по производству вакцин компании GSK за $7,1 млрд.

22 апреля 2014, 11:22

Швейцария/Великобритания: Novartis приобретет одно из подразделений GSK за $16 млрд

Швейцарская фармацевтическая компания Novartis заключила соглашение по приобретению подразделения GlaxoSmithKline (GSK), занимающегося разработкой лекарства от рака, за $16 млрд. В свою очередь, Novartis намерена продать свое подразделение по охране здоровья животных американской фармацевтической компании Eli Lilly & Co за $4,5 млрд, а также подразделение по производству вакцин компании GSK за $7,1 млрд.

03 февраля 2014, 17:53

Experimental Breast Cancer Drug Succeeds In Trial

 Feb 3 (Reuters) - Pfizer Inc's experimental breast cancer drug significantly improved patient survival rates in a mid-stage trial without their condition worsening, maintaining the company's lead in the race for a new treatment standard for the disease. The oral drug, palbociclib, is considered one of Pfizer's most valuable products in development. Analysts have said it could have annual sales of more than $5 billion if successful. Palbociclib was designated a "breakthrough" drug by the U.S. Food and Drug Administration last April based on initial data from the trial. The FDA grants "breakthrough" status to drugs that may offer substantial improvement over existing treatments for serious or life-threatening diseases. The status helps to speed up the approval process. The trial, called Paloma-1, tested the drug in post-menopausal patients in combination with the hormonal therapy letrozole. Results were compared with patients receiving only letrozole. Pfizer has started two late-stage trials of the drug - Paloma-2 and Paloma-3 - in patients with advanced breast cancer. Paloma-2 will test the same drug combination, palbociclib and letrozole, as an initial treatment for breast cancer. Paloma-3 will evaluate palbociclib in combination with another hormone therapy, fulvestrant, in women whose cancer has progressed after hormonal therapy. Palbociclib works by blocking two enzymes, cyclin dependent kinases (CDK) 4 and 6, which enable tumor cell growth. Companies trying to develop similar treatments include Novartis AG and Eli Lilly & Co. Breast cancer killed over 508,000 women worldwide in 2011, according to the World Health Organization. Pfizer shares were up about 1 percent at $30.75 in premarket trade on Monday.

Выбор редакции
30 января 2014, 17:03

США: квартальная прибыль Eli Lilly & Co совпала с прогнозами аналитиков

Американская фармацевтическая компания Eli Lilly & Co отчиталась о квартальной прибыли, совпавшей с ожиданиями аналитиков. Так, прибыль в четвертом квартале снизилась с $827 млн или 74 центов на акцию годом ранее до $728 млн или 67 центов на бумагу. При этом прибыль без учета некоторых статей составила 74 цента на бумагу, совпав со средними прогнозами аналитиков. Выручка за рассматриваемый период снизилась на 2% до $5,81 млрд, в то время как аналитики ожидали $5,46 млрд.

Выбор редакции
30 января 2014, 16:28

США: квартальная прибыль Eli Lilly & Co совпала с прогнозами аналитиков

Американская фармацевтическая компания Eli Lilly & Co отчиталась о квартальной прибыли, совпавшей с ожиданиями аналитиков. Так, прибыль в четвертом квартале снизилась с $827 млн или 74 центов на акцию годом ранее до $728 млн или 67 центов на бумагу. При этом прибыль без учета некоторых статей составила 74 цента на бумагу, совпав со средними прогнозами аналитиков. Выручка за рассматриваемый период снизилась на 2% до $5,81 млрд, в то время как аналитики ожидали $5,46 млрд.